Huafei Li

Dr. Huafei Li

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2018 in Nanomedicine
Verified
Journal Article
Closed access
HLHuafei Li
Huafei Li
HJHai Jin
Hai Jin
WWWei Wan
Wei Wan
CWCong Wu
Cong Wu
LWLixin Wei
Lixin Wei
Targeting nanoparticles to cancers for improved therapeutic efficacy and decreased side effects remains a popular concept in the past decades. Although the enhanced permeability and retention effect serves as a key rationale for all the currently commercialized nanoformulations, it does not enable uniform delivery of nanoparticles to all tumorous regions in all patients with sufficient quantities. Also, the increase in overall survival is often modest. Many factors may influence the delivering process of nanoparticles, which must be taken into consideration for the promise of nanomedicine in patients to be realized. Herein, we review the mechanisms and influencing factors during the delivery of cancer therapeutics and summarize current strategies that have been developed for the fabrication of smart drug delivery systems.

28 September 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
YTYuan Tian
Yuan Tian
XWXiaowei Wang
Xiaowei Wang
CWCong Wu
Cong Wu
JQJiaming Qiao
Jiaming Qiao
HJHai Jin
Hai Jin
HLHuafei Li
Huafei Li
Currently, even the most effective anti-cancer therapies are often limited by the development of drug resistance and tumor relapse, which is a major challenge facing current cancer research. A deep understanding of the molecular and biochemical bases of drug efficacy that can help predict the clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, have facilitated studies identifying and elucidating the underlying mechanisms. In this review, we focus on several important issues on cancer drug resistance and provide a framework for understanding the common ways by which cancers develop resistance to therapeutic agents. With the increasing arsenal of novel anticancer agents and techniques, there are now unprecedented opportunities to understand and overcome drug resistance. The proteolysis targeting chimera (PROTAC) technology, immunotherapy, nanomedicine, and real-time monitoring of drug response all provide effective approaches for combating drug resistance. In addition to the advancement of therapeutic technologies, the revolution of treatment concept is also of great importance. We can take advantage of the interplay between drug sensitive and resistant subclones for combating cancer. However, there remains a long way to go in the protracted war against cancer drug resistance.

28 August 2014 in Discover Nano
Verified
Journal Article
Open access
PDF file
CWCong Wu
Cong Wu
HLHuafei Li
Huafei Li
HZHe Zhao
He Zhao
WZWeiwei Zhang
Weiwei Zhang
YCYan Chen
Yan Chen
ADAnmei Deng
Anmei Deng
Unlike most malignancies, chemotherapy but not surgery plays the most important role in treating non-Hodgkin lymphoma (NHL). Currently, liposomes have been widely used to encapsulate chemotherapeutic drugs in treating solid tumors. However, higherin vivostability owns a much more important position for excellent antitumor efficacy in treating hematological malignancies. In this study, we finely fabricated a rituximab Fab fragment-decorated liposome based on 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), which can form intermolecular cross-linking through the diacetylenic group by ultra-violet (UV) irradiation. Our experimental results demonstrated that after the UV irradiation, the liposomes exhibit better serum stability and slower drug release with a decreased mean diameter of approximately 285 nm. The cellular uptake of adriamycin (ADR) by this Fab-navigated liposome was about four times of free drugs. Cytotoxicity assays against CD20+lymphoma cells showed that the half maximal (50%) inhibitory concentration (IC50) of ADR-loaded immunoliposome was only one fourth of free ADR at the same condition.In vivostudies were evaluated in lymphoma-bearing SCID mice. With the high serum stability, finely regulated structure, active targeting strategy via antigen-antibody reaction and passive targeting strategy via enhanced permeability and retention (EPR) effect, our liposome exhibits durable and potent antitumor activities both in the disseminated and localized human NHL xeno-transplant models.

1 January 2022
Verified
Journal Article
Closed access
RFRuyu Fan
Ruyu Fan
SHShipeng He
Shipeng He
YWYongqing Wang
Yongqing Wang
JQJiaming Qiao
Jiaming Qiao
HLHongcheng Liu
Hongcheng Liu
HLHuafei Li
Huafei Li

17 January 2017 in RSC Advances
Verified
Journal Article
Open access
PDF file
CWCong Wu
Cong Wu
WWWei Wan
Wei Wan
JZJi Zhu
Ji Zhu
HJHai Jin
Hai Jin
TZTiejun Zhao
Tiejun Zhao
HLHuafei Li
Huafei Li
Targeted therapy opened a new era for the treatment of malignancies. Recently, there is growing interest in the development of novel targeted ligands except for monoclonal antibodies (mAbs). Aptamers are a class of therapeutic oligonucleotides form specific three dimensional structures dictated by their sequences. Aptamers can bind to a wide range of targets with high sensitivity and specificity, making it an ideal candidate for disease diagnosis and therapy. Herein, an anti-CD20 DNA aptamer (ACDA) was successfully screened from Harvard library by systematic evolution of ligands by exponential enrichment (SELEX). Experimental results demonstrated that ACDA can bind to surface CD20 than Rituximab Fab fragments with stronger binding affinity. With mass arming ACDA to a long chain polyethyleneimine (PEI) polymer, the resultant aptamer–polymer conjugates (P-ACDA) can induce potent caspase dependent apoptosis in targeting Non-Hodgkin's Lymphoma (NHL) cells via the crosslink of cellular CD20. All the results indicated that ACDA not only can be developed as targeting ligands for specifically delivering diagnostic or therapeutic drugs, but also can themselves be effective therapeutic candidates in treating NHL, which deserves for further investigation in the clinic.

1 July 2022 in Nano Research
Verified
Journal Article
Closed access
PDF file
SFShini Feng
Shini Feng
PNPinyue Ni
Pinyue Ni
YGYan Gong
Yan Gong
BGBijiang Geng
Bijiang Geng
HLHui Li
Hui Li
HLHuafei Li
Huafei Li
Hepatic carcinoma (HC) is the sixth most frequently occurring malignancies and the third leading cause of cancer death worldwide. Sepantronium bromide (YM155) is a small molecule inhibitor of survivin, which has broad-spectrum anticancer therapeutic effects in various xenograft models. However, several-day continuous infusion is required to achieve greater antitumor efficacy because of rapid elimination from the blood circulation. Herein, a SMMC-7721 cancerous cyto-membrane-cloaked drug delivery system (DDS) (named as iM7721@GQD-YM), was developed for co-encapsulation of YM155 and graphene quantum dots (GQDs). Cytomembrane coating endowed iM7721@GQD-YM with effective targeting for homologous HC cells, excellent biocompatibility and favorable immunocompatibility for in vivo application. Surface decoration of iRGD peptide further enhanced its tumor targeting activity by iRGD-integrin recognition. In addition, under the irradiation of near-infrared ray (NIR), GQDs can directly kill tumors through photothermal effect and cause cell membrane rupture, accurately releasing YM155 at tumor sites. The physicochemical properties, in vivo and ex vivo anti-tumor efficacy, and mechanisms of iM7721@GQD-YM nanoparticles (NPs) were systematically investigated in this work. The experimental results clearly indicate that the versatile biomimetic DDS holds great potential for the treatment of HC, which merits further investigation in both pre-clinical and clinical studies.